Xifaxan®
rifaximin 550 mg tablets

You are cordially invited to learn more about a Live Educational Presentation entitled

Hepatic Encephalopathy: Addressing a Major Complication of Cirrhosis – Main OHE deck for PCPs

PRESENTED BY

Kimberly Brown, MD

Henry Ford Health System
Detroit, MI

Tuesday, June 30, 2026 at 6:00 PM ET

Ruth's Chris

314 South 4th Avenue
Ann Arbor, MI 48104-2104
Phone: (734) 585-5155

Please RSVP at least one week prior to the program to Danielle Fusco at 248-935-0857 or Danielle.Fusco@salix.com or by registering here: https://salixrsvp.com/program/417

This program is sponsored by Salix Pharmaceuticals. No CME/CE credit will be provided. Only physicians and health care professionals involved in providing patient care or product recommendations may attend this program. Attendance by guests or spouses is not permitted.

Please note that your name and the value of any meal/refreshment will be reported as required by federal and state transparency laws.

Additionally, you must notify the Salix Pharmaceuticals representative upon sign-in if you maintain a license to practice in Minnesota or Vermont. Due to the requirements of such state laws, we will not be able to pay for a meal/refreshment for individuals licensed in those states. However, you may attend the program and either: (i) opt out of the meal/refreshment; or (ii) pay for the meal/refreshment yourself. If you are a federal employee (e.g., employed by the VA), by attending the program, you are confirming that you have received any necessary approval from an appropriate ethics official to attend this event and partake in the incidental meal/refreshment provided.

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.

Please see additional Important Safety Information on next page and click here for Full Prescribing Information for XIFAXAN.

Salix Pharmaceuticals

Xifaxan®
rifaximin 550 mg tablets

IMPORTANT SAFETY INFORMATION (continued)

- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (Pgp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
- In a clinical study, the most common adverse reactions for XIFAXAN in HE (≥10%) were peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%).
- INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on the previous page and click here for Full Prescribing Information for XIFAXAN.

Salix Pharmaceuticals

Xifaxan®
rifaximin 550 mg tablets

You are cordially invited to learn more about a Live Educational Presentation entitled

This program is sponsored by Salix Pharmaceuticals. No CME/CE credit will be provided. Only physicians and health care professionals involved in providing patient care or product recommendations may attend this program. Attendance by guests or spouses is not permitted.

Please note that your name and the value of any meal/refreshment will be reported as required by federal and state transparency laws.

Additionally, you must notify the Salix Pharmaceuticals representative upon sign-in if you maintain a license to practice in Minnesota or Vermont. Due to the requirements of such state laws, we will not be able to pay for a meal/refreshment for individuals licensed in those states. However, you may attend the program and either: (i) opt out of the meal/refreshment; or (ii) pay for the meal/refreshment yourself. If you are a federal employee (e.g., employed by the VA), by attending the program, you are confirming that you have received any necessary approval from an appropriate ethics official to attend this event and partake in the incidental meal/refreshment provided.

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.

Please see additional Important Safety Information on next page and click here for Full Prescribing Information for XIFAXAN.

Salix Pharmaceuticals